Skip to main content

Table 4 Cost-effectiveness analysis for a single cohort in different attendance rate scenarios

From: Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis

Participation rate

Incremental costs (Million Euros)

Incremental effectivenes (QALYs)

ICER

0Ā % discount

ā€ƒBase Case

6.3

2,280

2,778

ā€ƒ50Ā % attendance

3.2

1,715

1,888

ā€ƒ30Ā % attendance

1.7

1,136

1,453

3Ā % discounta

ā€ƒBase Case

8.6

1,879

4,623

ā€ƒ50Ā % attendance

5.1

1,409

3,601

ā€ƒ30Ā % attendance

2.9

934

3,051

  1. QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio
  2. aDiscount applied beginning from the end of the evaluated period until death